Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics (MLYS) reported insider dispositions. David Rodman reported multiple sales of Common Stock over January–March 2026, including a broker-assisted cashless exercise reported on 03/12/2026 covering 6,348 shares. The filing lists several prior dispositions in the three months before that date with individual sale dates and share counts.
Mineralys Therapeutics reported fourth quarter and full-year 2025 results and highlighted major regulatory progress for its lead drug lorundrostat. The FDA accepted the company’s New Drug Application for lorundrostat in adults with hypertension in combination with other drugs, assigning a PDUFA target decision date of December 22, 2026.
Cash, cash equivalents and investments rose to $656.6 million as of December 31, 2025, from $198.2 million a year earlier, which the company expects to fund operations into 2028. For 2025, research and development expenses fell to $132.0 million and net loss narrowed to $154.7 million, reflecting completion of pivotal lorundrostat trials and higher interest income.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 2,171 shares of common stock at $16.00 per share and on the same day sold 2,171 shares at $26.84 per share in an open-market transaction. The filing describes these moves as an exercise or conversion of derivative securities followed by a sale. After the transactions, he directly owned 82,489 shares of common stock and held stock options covering 23,876 shares. The company notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance.
Mineralys Therapeutics insider transactions: David Rodman reported multiple sales of common stock, including a sale of 192,715 shares on 01/05/2026 for $6,749,100.06. The filing also shows numerous smaller open‑market sales in January–February 2026 and a broker‑assisted cashless exercise of 2,171 shares on 03/09/2026.
Mineralys Therapeutics reports that the U.S. FDA has accepted its New Drug Application (NDA) for lorundrostat to treat adult patients with hypertension in combination with other antihypertensive drugs. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
Topline data from the Phase 2 Explore-OSA exploratory trial in 48 overweight or obese adults with moderate-to-severe obstructive sleep apnea (OSA) and hypertension showed lorundrostat 50 mg did not improve apnea-hypopnea index (AHI), the primary endpoint, versus placebo after four weeks. However, lorundrostat produced an 11.1 mmHg systolic blood pressure reduction versus 1.0 mmHg with placebo and a 6.2 mmHg placebo-adjusted reduction in crossover analysis, with a favorable safety profile and no serum potassium above 5.5 mmol/L.
Mineralys Therapeutics, Inc. filed an initial ownership report for Chief Commercial Officer Warren Eric. It shows direct holdings of stock options covering 357,000 shares and another 51,300-share option, plus 38,400 shares of common stock. Footnotes describe restricted stock units granted for no cash consideration that vest over four years starting on February 19, 2026. One option grant vests 25% on the first anniversary of April 21, 2025, with the rest vesting in 36 monthly installments, while another vests in 48 equal monthly installments beginning after February 19, 2026.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics, Inc. reported an insider equity award arrangement involving RA Capital–affiliated entities. A partner of RA Capital Management serving on Mineralys’ board received 6,200 restricted stock units and a stock option for 8,300 shares of common stock, both granted for no additional cash consideration.
The RSUs vest in one annual installment after the grant date, while the option vests in 12 substantially equal monthly installments. According to the disclosures, these awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund III, with any shares or cash received offsetting advisory fees owed to RA Capital Management. The reporting persons disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest. Indirect holdings also include 5,456,521 shares of common stock held directly by the fund and 1,867,229 shares held directly by Nexus Fund III.
Mineralys Therapeutics, Inc. reported that Chief Executive Officer Jon Congleton received new equity-based compensation on February 19, 2026. He was granted 187,900 stock options, which vest in equal monthly installments over four years, with 1/48th of the total vesting each month after the grant date.
Congleton also acquired 140,900 shares of common stock through a grant of restricted stock units (RSUs) for no additional cash consideration. Each RSU represents one share of common stock and vests in four annual installments of 25% each on the yearly anniversaries of the grant date, bringing his direct common stock holdings to 780,051 shares.
SBLENDORIO GLENN reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics director Glenn Sblendorio reported equity awards consisting of 8,300 stock options and 6,200 shares of common stock on February 19, 2026. The common stock reflects restricted stock units granted for no cash consideration, vesting in one annual installment, while the options vest in 12 substantially equal monthly installments following the grant date.
Gold Alexander M reported acquisition or exercise transactions in this Form 4 filing.
Mineralys Therapeutics, Inc. director Alexander M. Gold reported awards of equity on February 19, 2026. He received a stock option covering 8,300 shares at a price of $0.0000 per share, and his option holdings after the transaction were 8,300 shares. He was also granted 6,200 shares of common stock, with total common stock holdings after the award of 6,200 shares.
According to the footnotes, the common stock reflects restricted stock units (RSUs) granted for no additional cash consideration, each representing one share of common stock that vests in one annual installment following the grant date. The stock option vests in 12 substantially equal monthly installments following the date of grant.